Bhargavi Patham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bhargavi Patham has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andres Calderon
Houston Methodist Hospital, Houston, Texas, US
4 shared publications - Jawairia Shakil
Houston Methodist Academic Institute, Houston, TX 77030, USA
4 shared publications - Alexsandra Rojas Drinnon
Houston Methodist Academic Institute, Houston, TX 77030, USA
3 shared publications - Maheswaran Dhanasekaran
Houston Methodist Academic Institute, Houston, TX 77030, USA
2 shared publications - Maria Aguilera Astudillo
Department of Medicine, Houston Methodist Hospital , Houston, TX 77030
2 shared publications - Abhishek Kansara
Houston Methodist Hospital Houston Texas US
1 shared publication
Latest Publications
- Open Access
Sexual Dimorphism and Menopausal Transition: A Narrative Review of the Metabolic and Physical Effects of Intermittent Fasting
The global rise in obesity and cardiometabolic disease represents a major public health concern and contributes significantly to cardiovascular morbidity and mortality. Contemporary Western dietary patterns and excess adiposity are strongly associated with atherosclerotic cardiovascular disease. Although pharmacologic therapies have expanded, lifestyle interventions remain the cornerstone of prevention and management. However, identifying sustainable and effective dietary approaches continues to be challenging given the wide range of available nutrition regimens. Intermittent fasting (IF) has emerged as a promising strategy for weight reduction and metabolic improvement. In this article, we review the physiological effects of IF, including metabolic switching, ketosis, and improvements in insulin sensitivity and inflammatory regulation. We also evaluate clinical evidence regarding the impact on cardiovascular risk, as well as its safety and tolerability. We examine the hormonal responses to IF based on sex. While early studies raised concerns regarding potential reproductive and endocrine disturbances, recent data suggest beneficial effects in both males and females. IF may modestly reduce testosterone in men without impairing muscle mass or strength and may improve metabolic and reproductive outcomes in women, particularly those with hyperandrogenic conditions such as polycystic ovarian syndrome, with favorable effects also observed in postmenopausal women, especially when combined with physical activity.
Open AccessSexual Dimorphism and Menopausal Transition: A Narrative Review of the Metabolic and Physical Effects of Intermittent Fasting
The global rise in obesity and cardiometabolic disease represents a major public health concern and contributes significantly to cardiovascular morbidity and mortality. Contemporary Western dietary patterns and excess adiposity are strongly associated with atherosclerotic cardiovascular disease. Although pharmacologic therapies have expanded, lifestyle interventions remain the cornerstone of prevention and management. However, identifying sustainable and effective dietary approaches continues to be challenging given the wide range of available nutrition regimens. Intermittent fasting (IF) has emerged as a promising strategy for weight reduction and metabolic improvement. In this article, we review the physiological effects of IF, including metabolic switching, ketosis, and improvements in insulin sensitivity and inflammatory regulation. We also evaluate clinical evidence regarding the impact on cardiovascular risk, as well as its safety and tolerability. We examine the hormonal responses to IF based on sex. While early studies raised concerns regarding potential reproductive and endocrine disturbances, recent data suggest beneficial effects in both males and females. IF may modestly reduce testosterone in men without impairing muscle mass or strength and may improve metabolic and reproductive outcomes in women, particularly those with hyperandrogenic conditions such as polycystic ovarian syndrome, with favorable effects also observed in postmenopausal women, especially when combined with physical activity.
- 20 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (9) , 1409-1418
A Deep Dive Into Endocrine and Reproductive Health in Patients With Cystic Fibrosis: Before and Beyond Solid Organ Transplantations
- 20 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (9) , 1409-1418
A Deep Dive Into Endocrine and Reproductive Health in Patients With Cystic Fibrosis: Before and Beyond Solid Organ Transplantations
- 20 January 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1273-e1280
Therapeutic Plasma Exchange in Severe Thyrotoxicosis: Clinical Observations From a Case Series
Context: Severe thyrotoxicosis and thyroid storm have a high morbidity and mortality risk and are commonly managed with antithyroid drugs. In some patients, a combination therapy with medications and thyroidectomy as definite treatment are required. Therapeutic Plasma Exchange (TPE) can be used as a temporizing measure to achieve thyroid hormone normalization and to prevent perioperative complications before surgery. Objective: We describe 6 cases of severe thyrotoxicosis and/or thyroid storm who underwent TPE as a bridge to thyroidectomy and present the clinical characteristics and outcomes. We aim to propose a preoperative thyroid hormone target. Methods: We collected data of 6 patients who were diagnosed with severe thyrotoxicosis or thyroid storm between April 2023 and April 2024 and that were treated with TPE due to high mortality risk or refractoriness to medical treatment. Data collected included the baseline clinical characteristics, laboratory data, clinical progress, and outcomes. Thyroid hormone levels at diagnosis, before initiation of TPE, and before thyroidectomy were compared using statistical analysis. Results: Four of 6 patients underwent thyroidectomy, and 2 patients died due to multiorgan dysfunction. The mean free T4 (fT4) level at diagnosis was 4.8 ng/dL (reference range, 0.8-1.8 ng/dL), 5.4 ng/dL pre-TPE, and 2.6 ng/dL prethyroidectomy, resulting in a mean difference of 2.8 ng/dL (51.7%) reduction (95% CI, 1.1-4.5; P = .01). The number of TPE treatments to reach a preoperative fT4 level of 2.5 ng/dL was 5.5 treatments (P = .03). Conclusion: These results reflect efficacy of TPE as a bridge to thyroidectomy and suggest that a preoperative fT4 goal of 2.5 to 3.3 can be considered in patients with severe thyrotoxicosis and thyroid storm that are refractory to medical treatment.
- 20 January 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1273-e1280
Therapeutic Plasma Exchange in Severe Thyrotoxicosis: Clinical Observations From a Case Series
Context: Severe thyrotoxicosis and thyroid storm have a high morbidity and mortality risk and are commonly managed with antithyroid drugs. In some patients, a combination therapy with medications and thyroidectomy as definite treatment are required. Therapeutic Plasma Exchange (TPE) can be used as a temporizing measure to achieve thyroid hormone normalization and to prevent perioperative complications before surgery. Objective: We describe 6 cases of severe thyrotoxicosis and/or thyroid storm who underwent TPE as a bridge to thyroidectomy and present the clinical characteristics and outcomes. We aim to propose a preoperative thyroid hormone target. Methods: We collected data of 6 patients who were diagnosed with severe thyrotoxicosis or thyroid storm between April 2023 and April 2024 and that were treated with TPE due to high mortality risk or refractoriness to medical treatment. Data collected included the baseline clinical characteristics, laboratory data, clinical progress, and outcomes. Thyroid hormone levels at diagnosis, before initiation of TPE, and before thyroidectomy were compared using statistical analysis. Results: Four of 6 patients underwent thyroidectomy, and 2 patients died due to multiorgan dysfunction. The mean free T4 (fT4) level at diagnosis was 4.8 ng/dL (reference range, 0.8-1.8 ng/dL), 5.4 ng/dL pre-TPE, and 2.6 ng/dL prethyroidectomy, resulting in a mean difference of 2.8 ng/dL (51.7%) reduction (95% CI, 1.1-4.5; P = .01). The number of TPE treatments to reach a preoperative fT4 level of 2.5 ng/dL was 5.5 treatments (P = .03). Conclusion: These results reflect efficacy of TPE as a bridge to thyroidectomy and suggest that a preoperative fT4 goal of 2.5 to 3.3 can be considered in patients with severe thyrotoxicosis and thyroid storm that are refractory to medical treatment.
- Open Access
- 1 May 2025
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 21 (1) , 48-50
Obesity and the Heart: Webcast March 18 2025
This 76-minute webcast features a conversation about “Obesity and the Heart”—the focus of Issue 21.2. Led by the issue’s editor, the discussion engages the authors on emerging themes and lessons learned while researching and writing the articles. View the video at https://vimeo.com/event/4867850.
- 1 May 2025
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 21 (1) , 48-50
Open AccessObesity and the Heart: Webcast March 18 2025
This 76-minute webcast features a conversation about “Obesity and the Heart”—the focus of Issue 21.2. Led by the issue’s editor, the discussion engages the authors on emerging themes and lessons learned while researching and writing the articles. View the video at https://vimeo.com/event/4867850.
- Open Access
- 18 February 2025
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 21 (2) , 62-73
Medical Management of Obesity: Current Trends and Future Perspectives
Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.
- 18 February 2025
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 21 (2) , 62-73
Open AccessMedical Management of Obesity: Current Trends and Future Perspectives
Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.